Despite their potential, new cancer drugs face several challenges. One major issue is drug resistance, where cancer cells mutate and become less responsive to treatment over time. This necessitates ongoing research to understand mechanisms of resistance and develop combination therapies to overcome it. Additionally, the high cost of developing these drugs often translates to expensive treatments, posing accessibility issues for patients. Regulatory hurdles also exist, as new drugs must undergo rigorous clinical trials to ensure safety and effectiveness before they reach the market.
